Caspofungin: The first licensed antifungal drug of the novel echinocandin class

Clinical Microbiology Newsletter

Volumn 26, Issue 11, 2004, Pages 81-85

  DiNubile, Mark J ^a   Motyl, Mary ^a   Sable, Carole A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN A; DEXAMETHASONE; EFAVIRENZ; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; PHENYTOIN; RIFAMPICIN; TACROLIMUS; TUBERCULOSTATIC AGENT;

ANAPHYLAXIS; ANEMIA; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; ASTHENIA; CANDIDA; CANDIDIASIS; CHILL; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; EDEMA; EOSINOPHILIA; ESOPHAGUS DISEASE; FATIGUE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG INFILTRATE; MAJOR CLINICAL STUDY; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PROTEINURIA; PRURITUS; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 2642540903     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2004.05.001     Document Type: Article

References (31)

1. Deresinski, S. and D. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36: 1445-1457.
2. Groll, A.H. and T. J. Walsh. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Exp. Opin. Investig. Drugs 10:1545-1558.
3. Valgus, J.M. 1991. Caspofungin: the first class of a new class of antifungal agents. Cancer Pract. 9:314-316.
4. Kurtz, M. and J. Rex. 2001. Glucan synthase inhibitors as antifungal agents. Adv. Prot. Chem. 56:423-475.
5. Villanueva, A. et al. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33:1529-1535.
6. Villanueva, A. et al. 2004. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294.
7. Arathoon, E.G. et al. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46:451-457.
8. Mora-Duarte, J. et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
9. Maertens, J. et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients [abstract no. M-868]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2002.
10. Walsh, T. et al. A randomized, double-blind, multicenter trial of caspofungin vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 2003.
11. Sable, C.A. et al. 2002. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis. 4:25-30.
12. Pacetti, S.A. and S. P. Gelone. 2003. Caspofungin acetate for treatment of invasive fungal infections. Ann. Pharmacother. 37:90-98.
13. Bachmann, S.P., T.F. Patterson, and J.L. Lopez-Ribot. 2002. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J. Clin. Microbiol. 40:2228-2230.
14. Collin, B., C.J. Clancy, and M.H. Nguyen. 1999. Antifungal resistance in non-albicans Candida species. Drug Resist. Updat. 2:9-14.
15. Kartsonis, N. et al. 2002. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune Defic. Syndr. 31:183-187.
16. Ostyn, B. et al. 2002. A multidrug, including voriconazole, resistant oral Candida infection in an AIDS patient effectively treated with echinocandin. J. Infect. 44:57-58.
17. Rogers, T.R. 2001. Optimal use of existing and new antifungal drugs. Curr. Opin. Crit. Care 7:238-241.
18. Muller, F.M. et al. 2000. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J. Antimicrob. Chemother. 46:338-340.
19. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard (document M27A). NCCLS, Wayne, PA.
20. Bowman, J.C. et al. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:3001-3012.
21. Douglas, C.M. et al. Caspofungin alone or in combination with itraconazole reduces fungal burden in a neutropenic guinea pig model of disseminated aspergillosis (abstract no. M-1819). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2002.
22. Arikan, S. et al. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.
23. Espinel-Ingroff, A. 2002. Antifungal susceptibility methods and their potential clinical relevance. Lab. Med. 33:626-631.
24. Kantarcioglu, A.S. 2001. Comparison of the ATB fungal method with the NCCLS broth macrodilution method (M27-A) for determining susceptibility of Candida clinical isolates. J. Chemother. 13:446-449.
25. Loeffler, J. and D.A. Stevens. 2003. Antifungal drug resistance. Clin. Infect. Dis. 36:S31-S41.
26. Pfaller, M.A. et al. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:3254-3259.
27. Quindos, G. et al. 2000. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 46:395-401.
28. Shalit, I. et al. 2003. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob. Agents Chemother. 47:1416-1418.
29. Pfaller, M.A., J. H.Rex, and M.G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin. Infect. Dis. 24:776-784.
30. Stone, J.A. et al. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
31. DiNubile, M.J. et al. 2002. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res. Hum. Retrovir. 18:903-908.